New JAMA meta-analysis is good news for Abbott’s psoriasis drug but approval hurdles remain
This article was originally published in Scrip
Leading dermatologists have published a new meta-analysis of safety data in psoriasis.
You may also be interested in...
Novartis has unveiled the first set of positive Phase II psoriasis data for its novel interleukin (IL)-17 inhibitor, AIN457 (secukinumab), at the European Academy of Dermatology and Venereology (EADV) meeting on 24 October. AIN457 is now undergoing mammoth Phase III trials, and as the most clinically advanced IL-17 inhibitor, and Datamonitor believes it has potential to be first in class should it continue to show strong efficacy and no new safety signals.